An Open-Label Trial of PEMF Therapy [Provant Infinity Therapy System] for Home Use in Postoperative Pain
Postoperative Pain

About this trial
This is an interventional treatment trial for Postoperative Pain
Eligibility Criteria
Inclusion Criteria:
1. Subject is ≥ 60 days postoperative. 2. Subject's average chronic postoperative pain over the preceding week is ≥4 and <9, based on the 11-point NPRS (0-10) at the Screening Visit.
3. Subject's age is greater than or equal to 22 years and less than 80 years of age.
4. Subject is willing and able to give written informed consent and to comply with all parts of the study protocol.
5. Female subjects must be postmenopausal, surgically sterile, abstinent, or, if of childbearing potential, practicing (or agrees to practice) an effective method of birth control if they are sexually active for the duration of the study. Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization.
Exclusion Criteria:
1. Subject has a history of previous solid organ transplant or severe renal disease (i.e. estimated creatinine clearance <30 mL/min).
2. Subject has previous or current history of primary or tertiary hyperparathyroidism, hypercalcemia, psychiatric disorder, alcohol dependency, Hepatitis B or C, or HIV infection.
3. According to the judgment of the Investigator, subject has clinically significant cardiovascular disease within 6 months prior to screening (unstable or poorly controlled hypertension, transient ischemic attack, myocardial infarction, unstable angina, arrhythmia, cardiac surgery, stent placement or angioplasty, or congestive heart failure).
4. Subject has a history of any uncontrolled medical illness that, in the investigator's judgment, places the subject at unacceptable risk for enrollment in a research trial with pulsed electromagnetic field therapy.
5. Subject requires or anticipates the need for surgery (other than minor outpatient surgical procedures, such as dental or minor cosmetic procedures) or extended travel during the treatment period.
6. Subject has received any investigational drug or device within 30 days prior to the Screening Visit.
7. Subject has a history of malignancy within the past 5 years in the treatment area.
8. Subject has severe mental health or psychiatric disorder that would interfere with study performance and/or assessments in the opinion of the Investigator.
9. Subject has a known history of drug or alcohol abuse within one year prior to the Screening Visit.
10. Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
11. Subject is currently pregnant or planning to become pregnant prior to Week 8.
12. Subject is unwilling or unable to follow study instructions or comply with the treatment regimen, diary documentation, and study visits.
Sites / Locations
- Physician's Research Group
- Valley Clinical Research
- Lake Internal Medicine Associates
- Palm Research Center
Arms of the Study
Arm 1
Experimental
Provant Infinity Therapy
Open-label treatment with Provant Infinity Therapy